Prognostic value of plasma level of superoxide dismutase in HBV-related acute-on-chronic liver failure
Authors:
Open Access
- 25 June 2022
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 22 (1) , 1-9
Abstract
Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is the most prevalent type of ACLF in China. The mortality rate of HBV-ACLF has decreased in recent years due to advances in treatment therapies; however, it is still above 50%. Many cases of HBV-ACLF are caused by HBV reactivation due to discontinuation of nucleoside analog treatment. The present study focused on plasma levels of superoxide dismutase (SOD) in HBV-ACLF patients and investigated whether the plasma level of SOD is a useful biomarker in assessing disease severity and predicting outcomes of HBV-ACLF patients, including patients treated with Entecavir (ETV) and patients who were withdrawn from ETV treatment. Methods: Plasma samples and clinical data from 200 HBV-ACLF patients and from age- and sex-matched cirrhotic and healthy controls were collected and analyzed. Plasma levels of SOD were measured using an ELISA commercial kit. Results: Among the HBV-ACLF patients, in the ETV withdrawal group, the mortality rate was higher than in the ETV group (69.95% vs 46.71%, P < 0.05). Moreover, HBV-DNA and SOD plasma levels were higher in the ETV withdrawal group than in the ETV group (Log10(HBV-DNA): 6.49 ± 0.24 vs 4.79 ± 0.14, P < 0.01; SOD: 463.1 ± 27.61 U/mL vs 397.2 ± 10.97 U/mL, P < 0.05). The mortality and liver transplantation rates were significantly higher in HBV-ACLF patients with plasma levels of SOD > 428 U/mL than in patients with plasma SOD levels ≤ 428 U/mL. Conclusions: Reactivation of HBV and elevated oxidative stress caused by discontinuation of ETV treatment are crucial factors in the pathogenesis of HBV-ACLF. Plasma level of SOD may serve as a useful biomarker in estimating disease severity and predicting outcomes of HBV-ACLF patients who stop ETV treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81800548)
This publication has 27 references indexed in Scilit:
- Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014Hepatology International, 2014
- Scoring systems predict the prognosis of acute-on-chronic hepatitis B liver failure: an evidence-based reviewExpert Review of Gastroenterology & Hepatology, 2014
- Systemic inflammation is associated with increased intrahepatic resistance and mortality in alcohol‐related acute‐on‐chronic liver failureLiver International, 2014
- Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM modelHepatology International, 2013
- Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negativeBMC Infectious Diseases, 2013
- Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failureClinical and Experimental Medicine, 2011
- Correlation between promoter methylation of glutathione‐S‐tranferase P1 and oxidative stress in acute‐on‐chronic hepatitis B liver failureJournal of Viral Hepatitis, 2011
- HIV and HCV Cooperatively Promote Hepatic Fibrogenesis via Induction of Reactive Oxygen Species and NFκBJournal of Biological Chemistry, 2011
- Hepatitis B virus replication causes oxidative stress in HepAD38 liver cellsMolecular and Cellular Biochemistry, 2006
- Fatal Fulminant Hepatitis B after Withdrawal of Prophylactic Lamivudine in Hematopoietic Stem Cell Transplantation PatientsInternational Journal of Hematology, 2005